Loss of phosphatase and tensin homolog (PTEN) in myeloid cells controls inflammatory bone destruction by regulating the osteoclastogenic potential of myeloid cells

Annals of the Rheumatic Diseases

Volumn 74, Issue 1, 2015, Pages 227-233

  Blüml, Stephan ^a   Friedrich, Martin ^a   Lohmeyer, Tobias ^a   Sahin, Emine ^a   Saferding, Victoria ^a   Brunner, Julia ^a   Puchner, Antonia ^a   Mandl, Peter ^a   Niederreiter, Birgit ^a   Smolen, Josef S ^a   Schabbauer, Gernot ^a   Redlich, Kurt ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN SH2; TRANSCRIPTION FACTOR NFAT; NFATC1 PROTEIN, MOUSE; OSTEOCLAST DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PTEN PROTEIN, MOUSE; TNFSF11 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DESTRUCTION; BONE MARROW CELL; CELL DIFFERENTIATION; CELL SURVIVAL; CONTROLLED STUDY; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; MORPHOMETRICS; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PROTEIN DEPLETION; QUANTITATIVE ANALYSIS; RHEUMATIC DISEASE; SIGNAL TRANSDUCTION; ANIMAL; EXPERIMENTAL ARTHRITIS; GENETICS; HUMAN; KNOCKOUT MOUSE; METABOLISM; TRANSGENIC MOUSE;

ANIMALS; ARTHRITIS, EXPERIMENTAL; BONE RESORPTION; CELL DIFFERENTIATION; HUMANS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MYELOID CELLS; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; PHOSPHATIDYLINOSITOL 3-KINASES; PTEN PHOSPHOHYDROLASE; RANK LIGAND;

EID: 84918522184     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203486     Document Type: Article

References (34)

1. Scott DL, Pugner K, Kaarela K, et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford) 2000;39:122-32.
2. Anandarajah AP, Schwarz EM. Bone loss in the spondyloarthropathies: role of osteoclast, RANKL, RANK and OPG in the spondyloarthropathies. Adv Exp Med Biol 2009;649:85-99.
3. Sanchez-Riera L, Wilson N, Kamalaraj N, et al. Osteoporosis and fragility fractures. Best Pract Res Clin Rheumatol 2011;24:793-810.
4. Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304-9.
5. Redlich K, Hayer S, Ricci R, et al. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 2002;110:1419-27.
6. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-42.
7. Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet 2003;4:638-49.
8. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-23.
9. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
10. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95:3597-602.
11. Wiktor-Jedrzejczak W, Bartocci A, Ferrante AW Jr, et al. Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc Natl Acad Sci USA 1990;87:4828-32.
12. Takayanagi H, Kim S, Koga T, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002;3:889-901.
13. Negishi-Koga T, Takayanagi H. Ca2+-NFATc1 signaling is an essential axis of osteoclast differentiation. Immunol Rev 2009;231:241-56.
14. Vogt PK, Hart JR, Gymnopoulos M, et al. Phosphatidylinositol 3-kinase: the oncoprotein. Curr Top Microbiol Immunol 2010;347:79-104.
15. Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol 2003;3:317-30.
16. Hawkins PT, Anderson KE, Davidson K, et al. Signalling through Class I PI3Ks in mammalian cells. Biochem Soc Trans 2006;34(Pt 5):647-62.
17. Leslie NR, Downes CP. PTEN function: how normal cells control it and tumour cells lose it. Biochem J 2004;382(Pt 1):1-11.
18. Parsons R. Human cancer, PTEN and the PI-3 kinase pathway. Semin Cell Dev Biol 2004;15:171-6.
19. Schabbauer G, Luyendyk J, Crozat K, et al. TLR4/CD14-mediated PI3K activation is an essential component of interferon-dependent VSV resistance in macrophages. Mol Immunol 2008;45:2790-6.
20. Gunzl P, Schabbauer G. Recent advances in the genetic analysis of PTEN and PI3K innate immune properties. Immunobiology 2008;213:759-65.
21. Gunzl P, Bauer K, Hainzl E, et al. Anti-inflammatory properties of the PI3K pathway are mediated by IL-10/DUSP regulation. J Leukoc Biol 2010;88:1259-69.
22. Heit B, Robbins SM, Downey CM, et al. PTEN functions to 'prioritize' chemotactic cues and prevent 'distraction' in migrating neutrophils. Nat Immunol 2008;9:743-52.
23. Subramanian KK, Jia Y, Zhu D, et al. Tumor suppressor PTEN is a physiologic suppressor of chemoattractant-mediated neutrophil functions. Blood 2007;109:4028-37.
24. Takeshita S, Namba N, Zhao JJ, et al. SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts. Nat Med 2002;8:943-9.
25. Zhou P, Kitaura H, Teitelbaum SL, et al. SHIP1 negatively regulates proliferation of osteoclast precursors via Akt-dependent alterations in D-type cyclins and p27. J Immunol 2006;177:8777-84.
26. Moon JB, Kim JH, Kim K, et al. Akt induces osteoclast differentiation through regulating the GSK3beta/NFATc1 signaling cascade. J Immunol 2012;188:163-9.
27. Cao H, Yu S, Yao Z, et al. Activating transcription factor 4 regulates osteoclast differentiation in mice. J Clin Invest 2010;120:2755-66.
28. Gingery A, Bradley E, Shaw A, et al. Phosphatidylinositol 3-kinase coordinately activates the MEK/ERK and AKT/NFkappaB pathways to maintain osteoclast survival. J Cell Biochem 2003;89:165-79.
29. Sugatani T, Alvarez U, Hruska KA. PTEN regulates RANKL- and osteopontin-stimulated signal transduction during osteoclast differentiation and cell motility. J Biol Chem 2003;278:5001-8.
30. Liu X, Bruxvoort KJ, Zylstra CR, et al. Lifelong accumulation of bone in mice lacking Pten in osteoblasts. Proc Natl Acad Sci USA 2007;104:2259-64.
31. Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991;10:4025-31.
32. Bluml S, Binder NB, Niederreiter B, et al. Anti-inflammatory effects of TNF on hematopoietic cells in the development of erosive arthritis. Arthritis Rheum 2010;62:1608-19.
33. Binder NB, Niederreiter B, Hoffmann O, et al. Estrogen-dependent and C-C chemokine receptor-2-dependent pathways determine osteoclast behavio r in osteoporosis. Nat Med 2009;15:417-24.
34. Liu H, Perlman H, Pagliari LJ, et al. Constitutively activated Akt-1 is vital for the survival of human monocyte-differentiated macrophages. Role of Mcl-1, independent of nuclear factor (NF)-kappaB, Bad, or caspase activation. J Exp Med 2001;194:113-26.